Figure 2.

Roflumilast reduces sputum acetyl-proline-glycine-proline (AcPGP). Sputa were analyzed in randomized patients. (A) Roflumilast treatment results in lower AcPGP levels compared with placebo after 12 weeks of therapy. (B) Roflumilast reduces sputum AcPGP by >50%. Following 12 weeks of treatment with (C) roflumilast or placebo, there were no statistical changes in sputum proline-glycine-proline (PGP). Open bars and circle represent the placebo group (n = 16), and solid bars and square represent the roflumilast group (n = 11). Values expressed as mean ± SEM. *P < 0.05. NS = not significant.